Abstract:Cisplatin-based chemotherapy is the current standard care for lung cancer patients; however, drug resistance frequently develops during treatment, thereby limiting therapeutic efficacy.The molecular mechanisms underlying cisplatin resistance remain elusive. In this study, we conducted an analysis of microarray data from the Gene Expression Omnibus (GEO) database under the accession numbers GSE21656, which encompassed expression profiling of cisplatin-resistant H460 (DDP-H460)and the parental cells (H460). Subsequently, we calculated the differentially expressed genes (DEGs) between DDP-H460 and H460. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs demonstrated significant impact on the Rap1, PI3K/AKT and MAPK signaling pathways. Moreover, protein and protein interaction (PPI) network analysis identified PRKCA, DET1, and UBE2N as hub genes that potentially contribute predominantly to cisplatin resistance. Ultimately, PRKCA was selected for validation due to its significant prognostic effect, which predicts unfavorable overall survival and disease-free survival in patients with lung cancer. Network analysis conducted on The Cancer Genome Atlas (TCGA) database revealed a strong gene-level correlation between PRKCA and TP53, CDKN2A, BYR2, TTN, KRAS, and PIK3CA; whereas at the protein level, it exhibited a high correlation with EGFR, Lck, Bcl2, and Syk. The in vitro experiments revealed that PRKCA was upregulated in the cisplatin-resistant A549 cells (DDP-A549), while knockdown of PRKCA increased DDP-A549 apoptosis upon cisplatin treatment. Moreover, we observed that PRKCA knockdown attenuated DDP-A549 proliferation, migration and invasion ability. Western blot analysis demonstrated that PRKCA knockdown downregulated phosphorylation of PI3K expression while upregulated the genes involved in ferroptosis signaling. In summary, our results elucidate the role of PRKCA in acquiring resistance to cisplatin and underscore its potential as a therapeutic target for cisplatin-resistant lung cancer.

Down-Regulation of Insulin-Like Growth Factor-Binding Protein 7 in Cisplatin-Resistant Non-Small Cell Lung Cancer

Abstract 829: Down-regulation of Insulin-Like Growth Factor-Binding Protein 7 in Cisplatin-Resistant Non-Small Cell Lung Cancer

Effect of Lung Resistance-Related Protein on the Resistance to Cisplatin in Human Ovarian Cancer Cell Lines.

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2

Identification of candidate genes and pathways in cisplatin-resistant NSCLC by integrated bioinformatics analysis

IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and dna repair associated molecules

LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress

MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer.

Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin

Blocking of SIRT7/FOXO3a Axis by miR-152-3p Enhances Cisplatin Sensitivity in Breast Cancer

Cancer-derived IgG involved in cisplatin resistance through PTP-BAS/Src/PDK1/AKT signaling pathway

Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP)

Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors

Integrated Analysis of DNA Methylation and Mrna Expression Profiling Reveals Candidate Genes Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer.

Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer

Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR‐497‐5p/mTOR

GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin

Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis

MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells